Hyogo Cancer Center /ID# 272553

Akashi-shi, Hyōgo 673-8558

0 studies enrolling now · 1 studies all time

What they study most

Advanced Solid Tumors Cancer

Studies at this site

• Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors — Running, not enrolling